Regulatory framework

Topic Details
Relevant statutory law(s)

Resolution of the Ministry of Health 627/2007

Industry code(s) of conduct

Code of good practices of Argentine Chamber of Medical Specialties (CAEME)

Other Not applicable

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Therapeutic Goods Act 1989 (Cth)
Therapeutic Goods Regulations 1990 (Cth), and Therapeutic Goods Advertising Code (No. 2) 2018 (Cth)
Health Practitioner Regulation National Law

Industry code(s) of conduct

Medicines Australia's Code of Conduct (19th Edition, 30 Mar 2020) (MA Code of Conduct), which provides a principles-based framework for appropriate and ethical decision making by pharmaceutical companies in Australia when promoting prescription medicines and interacting with, inter alia, HCPs.

Other Not applicable

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Pharmaceutical Act (Arzneimittelgesetz)

Industry code(s) of conduct PHARMIG Code of Conduct (amended version valid and applicable from 1 July 2020)
Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Belgian Law of 25 March 1964 on medicinal products

Belgian Act of 18 December 2016 on other provisions concerning health (so-called Sunshine Act)

Industry code(s) of conduct

Mdeon Code of Ethics

Code of Deontology

Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Brazilian Clean Company Act – BCCA (Law No. 12,846 of 01 August 2013)

Brazilian Criminal Code (Decree Law No. 2,848 of 7 December 1940)

Law No. 8,112 of 11 December 1990

Brazil's National Health Surveillance Agency – Anvisa

Industry code(s) of conduct

Association of the Pharmaceutical Research Industry - INTERFARMA Code of Conduct

Union of the Industry of Pharmaceutical Products - SINDUSFARMA Code of Ethics and Conduct

Association of the Over-The-Counter Medicines Industry - ABIMIP Code of Conduct

Other Not applicable

 

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Not applicable

Industry code(s) of conduct Innovative Medicines Canada Code ‎of Ethical Practices (Annotated ‎Version, 2020) of Innovative ‎Medicines Canada
Other Not applicable

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Chilean Sanitary Code

Industry code(s) of conduct Chilean Annex Code of Practice of the International Federation of Pharmaceutical Manufacturers & Associations Code
Other Not applicable

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Criminal Law of the People's Republic of China

Anti-Unfair Competition Law of the People's Republic of China

Law of the People's Republic of China on Medical Practitioners

Drug Administration Law of the People’s Republic of China

Industry code(s) of conduct

Code of Ethics for Chinese Medical Doctors

R&D-Based Pharmaceutical Association Committee Code of Practice (2019) ("RDPAC Code") (for member companies only, which include around 42 international pharmaceutical companies that have operations in China.)

Code of Ethics on Interactions with Health Care Professionals in China ("AdvaMed China Code") (for member companies only, which include 30 international pharmaceutical companies that have operations in China)

Other

Announcement of the National Medical Products Administration on Issuing the Administrative Measures for the Record-filing of Pharmaceutical Representatives(for Trial Implementation)

 

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Article 17 from Law 1751 of 2015

Article 133 from Law 1474 of 2011 

Both Law 1751 from 2015 and Law 1474 from 2011 expressly forbid the promotion or granting of any sort of benefits or gifts to health care professionals and workers that are part of the Health Social Security General System (Sistema General de Seguridad Social en Salud). This includes the HCP that provide services withing (i) the mandatory health plan, (ii) insurances and (iii) prepaid medical plans. 

Both cash and kind payments are covered by this prohibition. Furthermore, this ban is specifically addressed to the pharmaceutical companies, manufacturers, distributors, and suppliers of drugs or medical devices, equipment, inputs or any equivalent. 

Resolution 2881 from 2018 of the Ministry of Health and Social Protection 

Despite the abovementioned prohibitions, the Government has acknowledged that this kind of practices are common in the health related industries, and as such they cannot be forbidden per se, but it is needed to have a law that specifically regulates the conduct. 

The Ministry of Health issued Resolution 2881, by means of which it created a registry that seeks to collect information related to payments made by pharmaceutical companies to participants of the health sector as transferences of value (transferencias de valor). This registry called Registry of Valuable Transfers in the Hublic Sector (Registro de Transferencias de Valor en el Sector Salud) (hereinafter "RTSVV") has the purpose of improving transparency on the health industry and providing information to further stablish laws, regulation and policies to improve it.  The amounts of transfers mandatory for registry will be shown below. 

The Colombian Criminal Code (Law 599 from 2000) includes some crimes related to corruption that might be applicable to a lesser degree: 

  • Article 250-A: Corruption in the private sector.
  • Article 325-B: Omission of control in the health sector. Basically, it refers to the concealment of acts of corruption to existing monitoring methods and control procedures on the health industry. 

If one of the individuals is a public servant, then other crimes might be applicable. 

  • Articles 405, 406 & 407: are all related to briberies. Article 407 in particular alludes to the offering or giving money or utilities to public servants
  • Article 411-A: is relevant for private individuals who unduly influence public servants in order to obtain economic benefits.
Industry code(s) of conduct

AFIDRO’S Code of Ethics from 2019 (Asociación de Laboratorios Farmacéuticos de Investigación y Desarrollo) (Hereafter "AFIDRO"). 

ANDI's (Businessmen National Association) (Hereafter "ANDI") Chamber of Pharmaceutical Industry of Code of Ethics and Transparency

Other

Pact for the Transparency and Integrity of the Pharmaceutical Sector in Colombia:

This is an anti-corruption pact signed by members of ANDI and AFIDRO as well as the Association of Pharmaceutical Industries in Colombia-ASINFAR (Asociación de Industrias Farmacéuticas en Colombia). It was signed with the purpose of fighting corruption in the pharmaceutical industry. This pact intends to create or straighten their current codes of ethics and protocols.

 

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Main legal source of medicine law area in the Republic of the Croatia is the Croatian Medicinal Products Act (Cro. Zakon o lijekovima, Official Gazette of the Republic of Croatia No. 76/2013., 90/2014., 100/2018. – "Act"). With regard to advertisements of medical products, Articles 182 et seq. empower the Croatian Health Minister to enact an ordinance which will regulate the scope in question in detail. The key legal source of the subject matter at hand is therefore the Croatian Ordinance on the manner of advertising medicines (Cro. Pravilnik o načinu oglašavanja o lijekovima, Official Gazette of the Republic of Croatia No. 43/2015. – "Ordinance"). 

The English version of the Act is available online (whereby we note that the available version may not up to date). 

There is no (reliable) English version of the Ordinance available.

Industry code(s) of conduct

Code Of Conduct Of Innovative Pharmaceutical Companies in interactions with healthcare professionals, healthcare organizations and patient organizations ("Code") adopted by the General Assembly of the Innovative Pharmaceutical Initiative (Cro. Inovativna farmaceutska inicijativa). 

The English version of the Code is available online.

Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Act No. 378/2007 Coll., on Pharmaceuticals (Act on Pharmaceuticals)

Industry code(s) of conduct

AIFP (Association of Innovative Pharmaceutical Industry) Code of Practice – dated April 2020

Other Not applicable

Please also see European Union.

Last modified 23 Mar 2021

Topic Details
Relevant statutory law(s)

Danish Medicines Act

Executive Order 1153/2014 on Advertising for Medicinal Products

Industry code(s) of conduct The Pharmaceutical Industry’s Code of Practice on Promotion etc., of Medicinal Products aimed at Healthcare Professionals (The Promotion Code)
Other

The Guidance on The Pharmaceutical Industry's Code of Practice on Promotion etc., of Medicinal Products aimed at Healthcare Professionals (The Promotion Code) 

Guide 2014-12-29 no. 10356 about advertising etc. for medicines

Please also see European Union.

Last modified 12 Jan 2021

Topic Details
Relevant statutory law(s)

Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (hereinafter: "Directive")

Industry code(s) of conduct

EFPIA Code of Practice

IFPMA Code of Practice

Other Not applicable

Last modified 23 Mar 2021

Topic Details
Relevant statutory law(s)

The Finnish Medicines Act (395/1987) and Medicines Degree (693/1987), available in Finnish and Swedish at www.finlex.fi

Industry code(s) of conduct

Code of Ethics issued by Pharma Industry Finland (PIF)

Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

German Criminal Code ("StGB") – last amended December 21, 2020

German Act on Advertising in the Field of Healthcare ("HWG") – last amended December 09, 2020 (German language) 

German Act against Unfair Competition ("UWG") – last amended November 26, 2020

Industry code(s) of conduct

It should be noted that any interactions permitted or restricted under the applicable German industry codes are indicative only. Particularly, industry codes are not legally binding for German courts and competent authorities. However, under the circumstances of the individual case, they may also consider the industry codes when assessing the compliance of interactions between pharmaceutical companies and HCPs. 

FSA Code of Conduct Healthcare Professionals ("FSA Kodex Fachkreise") published by the German self-regulatory organization "Voluntary Self-Regulation of the Pharmaceutical Industry" ("Freiwillige Selbstkontrolle für die Arzneimittelindustrie e.V." – "FSA") – edition 2021 

FSA Transparency Code ("FSA Kodex Transparenz") – edition 2020

Other

"AKG Code of Conduct"("AKG Verhaltenskodex") published by the German self-regulatory organization "Pharmaceuticals and Cooperation in the Healthcare Sector" ("Arzneimittel und Kooperation im Gesundheitswesen e.V." – "AKG") – last amended on April 22, 2015. 

(Model) Professional Code for Physicians in Germany ("MBO-Ä") published by the German Federal Medical Association ("BÄK") including the professional codes for physicians published by the local German medical associations – last amended December 14, 2018 

(Model) Professional Code for Dentists ("MBO-ZÄ") published by the German Federal Dentists Association ("BZÄK") including the professional codes for dentists published by the local German dentists associations – last amended November 16, 2019 (German language)

Please also see European Union.

Last modified 22 Jan 2021

Topic Details
Relevant statutory law(s)

Legislative Decree 96/1973

Circular 27810/2018 of the National Organization for Medicines

Ministerial Decision ∆ΥΓ3α/Γ.Π 32221/2013

Industry code(s) of conduct

Code of Ethics on the promotion of prescription only medicinal products and the disclosure of benefits for healthcare professionals issued by the Hellenic Association of Pharmaceutical Companies

Other

Not applicable

Please also see European Union.

Last modified 26 Mar 2021

Topic Details
Relevant statutory law(s)

The Prevention of Bribery Ordinance (Cap. 201) ("PBO")

Industry code(s) of conduct

The Hong Kong Association of the Pharmaceutical Industry Code of Practice ("HKAPI Code of Practice")  

The Medical Council of Hong Kong Code of Professional Conduct for the Guidance of Regitered Medical Professionals ("Code of Conduct") 

Internal guidelines of the Hospital Authority (for HCPs employed by public hospitals; not available to the public).

Other

Acceptance of Advantages (Chief Executive's Permission) Notice 2010 (the "Notice")

 

Last modified 21 Jan 2021

Topic Details
Relevant statutory law(s)

The Ethics in Public Office Acts of 1995 and 2001

Criminal Justice (Corruption Offences) Act of 2018

Medicinal Products (Control of Advertising) Regulations, S.I. No. 541 of 2007 as amended

Industry code(s) of conduct

Irish Pharmaceutical Healthcare Association (IPHA) Code of Practice for the Pharmaceutical Industry (IPHA Code)

Health Products Regulatory Authority Code of Conduct (HPRA Code)

Medical Council Guide to Professional Conduct and Ethics (Medical Council Guide)

European Federation of Pharmaceutical Industries and Associations (EFPIA) Ethical Principles

Other Not applicable

Please also see European Union.

Last modified 9 Apr 2021

Topic Details
Relevant statutory law(s)

Legislative Decree 219/2006

Royal Decree 1265/1934

Industry code(s) of conduct Farmindustria Code of Ethics
Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Act on Prohibition of Private Monopolization and Maintenance of Fair Trade 

Act against Unjustifiable Premiums and Misleading Representations

Industry code(s) of conduct

Fair Competition Code (concerning Restriction on Premium Offers in Ethical Pharmaceutical Drugs Marketing Industry)("FCC")

Other JPMA Promotion Code for Prescription Drugs (as amended)

Last modified 2 Feb 2021

Topic Details
Relevant statutory law(s)

Law of 11 April 1983 on market launch and advertising of proprietary medicinal products and prefabricated medicines, as amended.

The Grand-Ducal Regulation of 15 December 1992 on market launch of medicinal products, as amended.

Industry code(s) of conduct

Code of Conduct issued by the Luxembourg Pharmaceutical Association

Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

General Health Law (Ley General de Salud) and relevant guidelines and regulations for sanitary and/or publicity purposes, among others

Industry code(s) of conduct

Codes of Good Practices of the Pharmaceutical Industry in Mexico (Códigos de Buenas Prácticas de la Industria Farmacéutica en México)

Code of Good Practices for Promotion (Código de Buenas Practicas de Promoción)

Both issued by the CETIFARMA (Board of Ethic and Transparency of the Pharmaceutical Industry in Mexico) (Consejo de Ética y Transparencia de la Industria Farmacéutica en México), available online.

Other No specific rules

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Polish Pharmaceutical Law of 6 September 2001

Industry code(s) of conduct

INFARMA Code of good practice

INFARMA Criteria of events assessment

PASMI Ethics Code (currently not available online)

PZPPF Ethics Code

Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Order 194/2015 on the legal framework for evaluation and approval of advertising of medicines for human use

Industry code(s) of conduct ARPIM Code
Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Article 67.1. (parts 1 and 2) of the Federal Law No. 61-FZ dated April 12, 2010 "On Circulation of Pharmaceuticals" ("Pharmaceuticals Law")

Industry code(s) of conduct Not applicable
Other Not applicable

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Law of the General Food and Drug Authority 13/02/2007 

Pharmaceutical Institutions and Products Law 

Tourism Law

Industry code(s) of conduct

Guideline For Good Clinical Practice (GCP) E6(R2)

Drug Master File: Guidance for Submission

Guidance for Priority Review of Product Registration

Regulations of Tourism Law 

See sfda.gov.sa and mt.gov.sa.

Other Not applicable

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Act No. 362/2011 Coll. on medicinal products and medical devices as amended ("Act on medical products")

Industry code(s) of conduct

Code of conduct of the Association of the Innovative Pharmaceutical Industry ("AIFP Code of Conduct") 

Code of Ethics of Association of Suppliers of Drugs and Medical Devices ("ADL Code of Conduct") 

Code of Ethics of Association for Generic and Biosimal Drugs ("GENAS Code of Conduct")

Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Slovenian Medicinal Products Act (Zakon o zdravilih; ZZdr-2), available in Slovene and English* 

* The translation in English is not up-to-date with the latest Medicinal Products Act

Slovenian Rules on advertising of medicines (available in Slovene) (Pravilnik o oglaševanju zdravil)

Industry code(s) of conduct

Code on cooperation with healthcare professionals (Kodeks sodelovanja z zdravstvenimi delavci – Kodeks OSZRp) of the Forum of International Research and Development Pharmaceutical Companies (Mednarodni forum znanstvenoraziskovalnih farmacevtskih družb, GIZ)

(hereinafter the "Code")

Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Spanish Royal Decree 1/2015 of 24 July, approving the consolidated text of the Law on Guarantees and Rational Use of Medicines

Industry code(s) of conduct

FarmaIndustria Code

Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Not applicable

Industry code(s) of conduct

Ethical Rules for the Pharmaceutical Industry

Other Not applicable

Please also see European Union.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Federal Law No. 8 of 2019 On Medical Products, the Profession of Pharmacy and Pharmaceutical Facilities. 

Ministerial Resolution No. 1448 of 2017 On Adoption of Code of Ethics and Professional Conduct for Health Professionals.

Industry code(s) of conduct UAE Ministry of Health & Prevention ("MOHAP") Code of Ethical Practices for the Promotion and Distribution of Medical Products. ("MOHAP COE").
Other No specific rules.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

The Human Medicines Regulations 2012 

Please also see European Union. Following Brexit, EU legislation as it applied to the United Kingdom on 31 December 2020 is now a part of the United Kingdom’s domestic legislation.

Industry code(s) of conduct

The ABPI Code of Practice ("ABPI") 

PAGB Code of Practice ("PAGB") 

GMC Code of Good Medical Practice ("GMC") 

Blue Guide (Advertising and Promotion of Medicines in the UK) ("Blue Guide") 

Other Not applicable.

Last modified 15 Jan 2021

Topic Details
Relevant statutory law(s)

Federal Laws & Implementing Regulations, & Government-Issued Guidance

Various federal laws and implementing regulations may be implicated in connection with providing anything of value to healthcare professionals ("HCPs"), under laws designed to prevent fraud, waste, and abuse ("FW&A") in government healthcare programs. Enforcement action and settlement history provide insight on the federal government’s perspective on these matters.  The federal government also issues guidance that may provide insight on the way it views transfers of value to HCPs.  Examples:

Federal Anti-Kickback Statute (42 U.S.C. § 1320a-7b(b)):

Prohibits providing remuneration in any form with the intent to induce or reward for, the prescribing, or arranging for or recommending the prescribing, of a product or service that is reimbursed by a federal healthcare program.  Does not establish specific appropriate amounts to be spent on HCPs related to accommodations, travel, or meals.

Physician Payment Sunshine Act (42 U.S.C. § 1320a-7h) and Implementing Regulations (42 C.F.R. Part 403, Subpart I):

Requires applicable manufacturers to track and to submit information regarding payments made to certain US HCPs.  Does not establish appropriate amounts to be spent on HCPs related to accommodations, travel, or meals; rather, addresses tracking and transparency obligations.  Individual payments of de minimis value (adjusted annually; currently $11.04) are exempt from the reporting requirement, although tracking is required because reporting is triggered if the aggregate payments to a particular HCP exceed a certain amount (adjusted annually; currently $110.40).

Federal (Government-Issued) Guidance:

US federal agencies issue guidance (e.g., OIG guidance including the HHS-OIG Compliance Program Guidance for Pharmaceutical Manufacturers (the "HHS-OIG Guidance", available here), Advisory Opinions, Special Fraud Alerts, etc.) to the life sciences and healthcare industries on various activities that may include guidance and interpretation relative to items of value provided to HCPs.  

State Laws & Implementing Regulations

FW&A Laws Including Any Payor Statutes:

Nearly all states have adopted FW&A laws that are generally analogous to the federal laws, but which in some cases apply more broadly than the federal laws (e.g., regardless of payor).

Marketing and Gift Laws: 

State marketing and gift laws should be considered. The exact applicability and scope will vary, and the landscape is subject to change, but a number of states have established compliance program requirements and/or impose restrictions on (and/or requirements related to) items or transfers of value being offered to HCPs in a particular state. Examples of jurisdictions with laws of this type:

  • California[1]
  • Connecticut[2]
  • District of Columbia[3]
  • Maine[4]
  • Massachusetts[5]
  • Minnesota[6]
  • New Jersey[7]
  • Vermont[8

Other Points to Consider (Not Addressed in this Survey): In some cases even cities (for example, the City of Chicago) may issue requirements governing marketing to HCPs;[9] and there may be other state laws applicable more broadly to gifts or other items of value (including hospitality) to state employees, with whom the life sciences industry may interact (for example, Louisiana). Further, healthcare professionals are governed by state professional licensure and related ethical requirements, the specifics of which may vary from state-to-state, and in addition the American Medical Association ("AMA") Code of Medical Ethics provides guidance regarding industry-provided gifts and subsidies for physicians. Further, healthcare institutions may have their own internal policies that prohibit or limit the receipt of hospitality. 

Footnotes

[1] Cal. Health & Safety Code § 119402.
[2] Conn. Gen. Stat. § 21a-70e.
[3] D.C. Code § 48-833.01.
[4] Me. Rev. Stat. tit. 32 § 13759; 02-392 C.M.R. ch. 12, § 7.
[5] Mass. Gen. Laws ch. 16 § 111N.
[6] Minn. Stat. § 151.461.
[7] N.J. Admin. Code § 13:45J.
[8] Vt. Stat. tit. 18 § 4631a.
[9] Chicago Municipal Code § 4-6-310(h)(1).
Industry code(s) of conduct

PhRMA Code on Interactions with Healthcare Professionals (last revised September 2019)

AdvaMed Code of Ethics (effective January 1, 2020)

Other

As explained, because a number of the standards cross-reference and incorporate others by reference, it is prudent to consider the landscape as a whole when approaching the US market. 

General Principle in the US: US government- and industry-issued guidance generally distinguish between two categories:

  • The potential for an industry role relative to travel and hospitality expenses (payment for, or reimbursement for, such expenses) in connection with company-sponsored events, meetings, or HCP services. This may include some meetings with educational or scientific content, but the content is controlled by the company. This category may also include travel and hospitality associated with HCPs engaged to provide services for the company (e.g., consultants or clinical investigators).  This category is the focus of the US responses for this survey.
  • The potential for industry financial support in connection with independent continuing medical education ("CME") or similar third-party conferences or events where the company does not control or influence content. This category is further explained in Online Conferences. Under industry codes, any financial support should be provided to conference organizers, and the conference organizers in turn should apply appropriate standards to its use.

Last modified 15 Jan 2021

Argentina

Argentina

Topic Details
Relevant statutory law(s)

Resolution of the Ministry of Health 627/2007

Industry code(s) of conduct

Code of good practices of Argentine Chamber of Medical Specialties (CAEME)

Other Not applicable

Last modified 15 Jan 2021

Argentina

Argentina

Topic Details
Competent authority/authorities enforcing the above statutory law(s)

Argentinian Ministry of Health

Competent authority/authorities enforcing the above code(s) of conduct Argentine Chamber of Medical Specialties (CAEME)
Competent authorities enforcing any other provisions indicated above Not applicable

 

Last modified 15 Jan 2021

Argentina

Argentina

Topic Detail
Restrictions on event locations (e.g., events abroad, touristic locations, mountain or beach locations during winter/summer season, etc)

No event should take place outside the Argentine Republic, unless there are logistical or security reasons for holding it abroad (e.g. where most of the participants guests come from abroad and/or where the relevant resource or expertise is located abroad).

Last modified 15 Jan 2021

Argentina

Argentina

Topic Details
Restrictions or requirements regarding event venues (e.g., resorts, castles, SPAs, proximity to transport connections or centers with relevant medical expertise, etc)  

Luxurious venues should not be selected for hosting events.

Last modified 15 Jan 2021

Argentina

Argentina

Topic Details
Restrictions or requirements regarding accommodation provided to HCPs (e.g. five star hotels, maximum number of nights, minimum duration of events, etc.) Accommodation may be provided to HCPs only and it should not include sponsorship or organization of entertainment or leisure activities (e.g. sporting events, musical events, etc.).

Last modified 15 Jan 2021

Argentina

Argentina

Topic Detail
Restrictions on air travel (e.g. economy class only; minimum flight duration for business class) No specific rules
Restriction on train transportation (class; duration; etc.) No specific rules
Other restrictions regarding travel No specific rules

Last modified 15 Jan 2021

Argentina

Argentina

Topic Details
Limitation on providing meals (e.g. only refreshment for events lasting for half a day or more) No specific rules
Maximum value for meals (e.g., EUR 60) – please specify by meal (breakfast, lunch, dinner) where applicable No specific rules
Restrictions on where meals can be provided? (e.g. no Michelin-starred restaurant) No specific rules
Other restriction (e.g. no alcohol may be offered) No specific rules

Last modified 15 Jan 2021

Argentina

Argentina

Topic Details
Rules applicable to family members travelling together with HCPs to the event location. No specific rules

Last modified 15 Jan 2021

Argentina

Argentina

Topic Details
Rules originally designed for traditional events (described in previous points) but applicable also to online conferences No specific rules
Additional rules applicable specifically to online conferences (incl. communication / advertising rules in relation to events attended by multinational audience) No specific rules

Last modified 15 Jan 2021

Argentina

Argentina

Topic Details
Specific rules applicable to promotional events organized by/on behalf of MAH in comparison to independent scientific events described in previous points (incl. event location, venue, accommodation, transport, meals, family members, online conferences No specific rules

Last modified 15 Jan 2021